Skip to main content

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
Cancel
×
×
Home
  • Home
Article
  • Cited by 4
  • Cited by
    Crossref Citations
    Crossref logo
    This article has been cited by the following publications. This list is generated based on data provided by CrossRef.
    Panatto, Donatella Amicizia, Daniela Tanzi, Elisabetta Bianchi, Silvia Frati, Elena Rosanna Zotti, Carla Maria Lai, Piero Luigi Bechini, Angela Rossi, Stefania and Gasparini, Roberto 2013. Prevalence of human papillomavirus in young Italian women with normal cytology: how should we adapt the national vaccination policy?. BMC Infectious Diseases, Vol. 13, Issue. 1,
    Bianchi, Silvia Frati, Elena Rosanna Panatto, Donatella Martinelli, Marianna Amicizia, Daniela Zotti, Carla Maria Martinese, Morena Bonanni, Paolo Boccalini, Sara Coppola, Rosa Cristina Masia, Giuseppina Meloni, Angelo Castiglia, Paolo Piana, Andrea Gasparini, Roberto Tanzi, Elisabetta and Tang, Julian W. 2013. Detection and Genotyping of Human Papillomavirus in Urine Samples from Unvaccinated Male and Female Adolescents in Italy. PLoS ONE, Vol. 8, Issue. 11, p. e79719.
    Panatto, Donatella Amicizia, Daniela Trucchi, Cecilia Casabona, Francesca Lai, Piero Luigi Bonanni, Paolo Boccalini, Sara Bechini, Angela Tiscione, Emilia Zotti, Carla Maria Coppola, Rosa Cristina Masia, Giuseppina Meloni, Angelo Castiglia, Paolo Piana, Andrea and Gasparini, Roberto 2012. Sexual behaviour and risk factors for the acquisition of human papillomavirus infections in young people in Italy: suggestions for future vaccination policies. BMC Public Health, Vol. 12, Issue. 1,
    Buonaguro, Franco M Tornesello, Maria Lina and Buonaguro, Luigi 2011. New adjuvants in evolving vaccine strategies. Expert Opinion on Biological Therapy, Vol. 11, Issue. 7, p. 827.
    ×
  • Get access
    Add to cart USD35.00
    Check if you have access via personal or institutional login
    Log in Register Recommend to librarian

Human papillomavirus vaccination: what is the best choice? A comparison of 16 strategies by means of a decisional model

  • R. GASPARINI (a1), D. AMICIZIA (a1), P. MANFREDI (a2), F. ANSALDI (a1), C. LUCIONI (a3), G. GALLELLI (a1) and D. PANATTO (a1)...
Summary

Some European countries decided to include human papillomavirus (HPV) vaccines in national immunization schedules. In order to help decision makers choose the best vaccination policy for females, a decisional model has been developed. The study was performed from the National Health Service perspective. Several hypotheses of multi-cohort vaccination policies were compared. ‘Potentially avoidable infections’ were chosen as the outcome. The model envisioned a short-term scenario (2008–2011). The best policy was that of vaccinating 12-year-olds and, a year later, those aged 14–16 years; the most expensive strategy was that of vaccinating 12-year-old females and, after 1 year, vaccinating those aged 15, 18 and 25 years. The sensitivity analysis showed that coverage rate has a great effect on the cost of avoidable infections. The study offers stake-holders an important datum-point for the choice of the best HPV policy vaccination in the short term. Indeed, it could generate interesting savings for the National Health Service and a rapid HPV immunization of young girls.

Copyright
COPYRIGHT: © 2008 Cambridge University Press
Corresponding author
*Author for correspondence: Professor R. Gasparini, Department of Health Sciences, University of Genoa, Via Pastore 1, 16132 Genova, Italy. (Email: gasparini@unige.it)
References
Hide All
1. Bosch, FX, et al. The causal relation between human papillomavirus and cervical cancer. Journal of Clinical Pathology 2002; 55: 244–265.
2. Dasbash, EJ, Elbasha, H, Insinua, RP. Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease. Epidemiologic Reviews 2006; 28: 88–100.
3. Elbasha, EH, Dasbach, EJ, Insigna, RP. Model for assessing human papillomavirus vaccination strategies. Emerging Infectious Disease 2007; 13: 28–41.
4. Beck, JR, Pauker, SG. The Markov process in medical prognosis. Medical Decision Making 1983; 3: 419–458.
5. Elbasha, EH, Galvani, AP. Vaccination against multiple HPV types. Mathematical Biosciences 2005; 197: 88–117.
6. Plummer, M, et al. A 2-years prospective study of HPV persistence among women with Ascus or LSIL cytology. Journal of Infectious Diseases 2007; 195: 1582–1589.
7. ISTAT 14th Italian population census. 21 October 2001 (www.demoistat.it). Accessed 8 January 2008.
8. Winer, RL, et al. Risk of female human papillomavirus acquisition associated with first male sex partner. Journal of Infectious Diseases 2008; 197: 279–282.
9. Winer, RL, et al. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. American Journal of Epidemiology 2003; 157: 218–226.
10. Brown, DR, et al. A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women. Journal of Infectious Diseases 2005; 191: 182–192.
11. Sharma, R, Sharma, CL. Quadrivalent human papillomavirus recombinant vaccine: the first vaccine for cervical cancers. Journal of Cancer Research and Therapeutics 2007; 3: 92–95.
12. Garnett, GP, et al. Modelling the impact of HPV vaccines on cervical cancer and screening programmes. Vaccine 2006; 24 (Suppl. 3): 178–86.
13. Munoz, N, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. New England Journal of Medicine 2003; 348: 518–527.
14. Pagliusi, SR, et al. Efficacy and other milestones for human papillomavirus vaccine introduction. Vaccine 2004; 23: 569–578.
15. Mao, C, et al. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia. A randomized controlled trial. Obstretics and Gynecology 2006; 107: 18–27.
16. Paavonen, J, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007; 369: 2161–2170.
17. Joura, EA, et al. Efficacy of a quadrivalent prophylactic human against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet 2007; 369: 1693–1702.
18. Harper, DM, et al. Sustained efficacy up to 4–5 years of a bivalent L1 virus-like particle vaccine against human Papillomavirus types 16 and 18: follow-up from a randomised trial. Lancet 2006; 367: 1247–1255.
19. Villa, LL, et al. High sustained efficacy of a prophylactic quadrivalent human Papillomavirus types 6/11/16/18 virus-like particle vaccine through 5 years of follow-up. British Journal of Cancer 2006; 95: 1459–1466.
20. Sewell, EC, Jacobson, SH, Weniger, BG. ‘Reverse engineering’ a formulary selection algorithm to determine the economic value of pentavalent and hexavalent combination vaccines. Pediatric Infectious Disease Journal 2001; 20 (Suppl. 11): S45–S56.
21. Coudeville, L, et al. Varicella vaccination in Italy: an economic evaluation of different scenarios. Pharmacoeconomics 2004; 22: 839–855.
22. Bosch, FX, de, Sanjosé S. The epidemiology of human papillomavirus infection and cervical cancer. Disease Markers 2007; 23: 213–227.
23. Woodman, CB, Collins, SI, Young, LS. The natural history of cervical HPV infection: unresolved issues. Nature Reviews Cancer 2007; 7: 11–22.
24. Barnabas, RV, et al. Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling Analysis. PLOS Medicine 2006; 3: 624–632.
25. Markowitz, LE, et al. Quadrivalent human papillomavirus vaccine recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbidity and Mortality Weekly Report 2007; 56: 1–24.
26. Saslow, D, et al. American Cancer Society Guideline for human Papillomavirus (HPV). Vaccine use to prevent cervical cancer and its precursors. A Cancer Journal for Clinicians 2007; 57: 7–28.
27. Garland, SM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. New England Journal of Medicine 2007; 356: 1928–1943.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Epidemiology & Infection
  • ISSN: 0950-2688
  • EISSN: 1469-4409
  • URL: /core/journals/epidemiology-and-infection
Please enter your name
Please enter a valid email address
Who would you like to send this to? *

CAPTCHA *

Skip to the audio challenge
×

Keywords:

Metrics

Full text views

Total number of HTML views: 3
Total number of PDF views: 15 *
Loading metrics...

Abstract views

Total abstract views: 96 *
Loading metrics...

* Views captured on Cambridge Core between September 2016 - 13th June 2018. This data will be updated every 24 hours.

Cancel
Confirm
×